Literature DB >> 31187696

Cantharidin decreased viable cell number in human osteosarcoma U-2 OS cells through G2/M phase arrest and induction of cell apoptosis.

Chia-Ching Chen1, Fu-Shin Chueh2, Shu-Fen Peng1, Wen-Wen Huang1, Chang-Hai Tsai3,4, Fuu-Jen Tsai4,5, Chih-Yang Huang6,7,8,9,10,11,12, Chih-Hsin Tang8,9,12, Jai-Sing Yang10, Yuan-Man Hsu1, Mei-Chin Yin2,10, Yi-Ping Huang11, Jing-Gung Chung1,12.   

Abstract

Cantharidin (CTD), a sesquiterpenoid bioactive substance, has been reported to exhibit anticancer activity against various types of cancer cells. The aim of the present study was to investigate the apoptosis effects and the underlying mechanisms of CTD on osteosarcoma U-2 OS cells. Results showed that CTD induced cell morphologic changes, reduced total viable cells, induced DNA damage, and G2/M phase arrest. CTD increased the production of reactive oxygen species and Ca2+, and elevated the activities of caspase-3 and -9, but decreased the level of mitochondrial membrane potential. Furthermore, CTD increased the ROS- and ER stress-associated protein expressions and increased the levels of pro-apoptosis-associated proteins, but decreased that of anti-apoptosis-associated proteins. Based on these observations, we suggested that CTD decreased cell number through G2/M phase arrest and the induction of cell apoptosis in U-2 OS cells and CTD could be a potential candidate for osteosarcoma treatments.

Entities:  

Keywords:  Cantharidin; G/M phase arrest; apoptosis; cell cycle; osteosarcoma U-2 OS cells

Mesh:

Substances:

Year:  2019        PMID: 31187696     DOI: 10.1080/09168451.2019.1627182

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  5 in total

1.  Drug Screening of Potential Multiple Target Inhibitors for Estrogen Receptor-α-positive Breast Cancer.

Authors:  Juan-Cheng Yang; Yang-Chang Wu; Yun-Hao Dai; Guan-Yu Chen; Chih-Hsin Tang; Wei-Chien Huang
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 2.  Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.

Authors:  Yulin Ren; A Douglas Kinghorn
Journal:  Bioorg Med Chem       Date:  2021-01-09       Impact factor: 3.641

Review 3.  Anticancer Attributes of Cantharidin: Involved Molecular Mechanisms and Pathways.

Authors:  Faiza Naz; Yixin Wu; Nan Zhang; Zhao Yang; Changyuan Yu
Journal:  Molecules       Date:  2020-07-19       Impact factor: 4.411

4.  Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma.

Authors:  Xiang Lu Ji; Ming He
Journal:  Aging (Albany NY)       Date:  2019-08-15       Impact factor: 5.682

5.  Cantharidin inhibits osteosarcoma proliferation and metastasis by directly targeting miR-214-3p/DKK3 axis to inactivate β-catenin nuclear translocation and LEF1 translation.

Authors:  Shaopu Hu; Junli Chang; Hongfeng Ruan; Wenlan Zhi; Xiaobo Wang; Fulai Zhao; Xiaoping Ma; Xingyuan Sun; Qianqian Liang; Hao Xu; Yongjun Wang; Yanping Yang
Journal:  Int J Biol Sci       Date:  2021-06-16       Impact factor: 6.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.